1
|
Horváth ÁI, Szentes N, Tékus V, Payrits M, Szőke É, Oláh E, Garami A, Fliszár-Nyúl E, Poór M, Sár C, Kálai T, Pál S, Percze K, Scholz ÉN, Mészáros T, Tóth B, Mátyus P, Helyes Z. Proof-of-Concept for the Analgesic Effect and Thermoregulatory Safety of Orally Administered Multi-Target Compound SZV 1287 in Mice: A Novel Drug Candidate for Neuropathic Pain. Biomedicines 2021; 9:biomedicines9070749. [PMID: 34209525 PMCID: PMC8301340 DOI: 10.3390/biomedicines9070749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 06/18/2021] [Accepted: 06/22/2021] [Indexed: 11/24/2022] Open
Abstract
SZV 1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl)propanal oxime) is a novel multi-target candidate under preclinical development for neuropathic pain. It inhibits amine oxidase copper containing 3, transient receptor potential ankyrin 1 and vanilloid 1 (TRPV1) receptors. Mainly under acidic conditions, it is transformed to the cyclooxygenase inhibitor oxaprozin, which is ineffective for neuropathy. Therefore, an enterosolvent capsule is suggested for oral formulation, which we investigated for nociception, basic kinetics, and thermoregulatory safety in mice. The antihyperalgesic effect of SZV 1287 (10, 20, 50, and 200 mg/kg, p.o.) was determined in partial sciatic nerve ligation-induced traumatic neuropathy by aesthesiometry, brain and plasma concentrations by HPLC, and deep body temperature by thermometry. Its effect on proton-induced TRPV1 activation involved in thermoregulation was assessed by microfluorimetry in cultured trigeminal neurons. The three higher SZV 1287 doses significantly, but not dose-dependently, reduced neuropathic hyperalgesia by 50% of its maximal effect. It was quickly absorbed; plasma concentration was stable for 2 h, and it entered into the brain. Although SZV 1287 significantly decreased the proton-induced TRPV1-mediated calcium-influx potentially leading to hyperthermia, it did not alter deep body temperature. Oral SZV 1287 inhibited neuropathic hyperalgesia and, despite TRPV1 antagonistic action and brain penetration, it did not influence thermoregulation, which makes it a promising analgesic candidate.
Collapse
Affiliation(s)
- Ádám István Horváth
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary; (Á.I.H.); (N.S.); (V.T.); (M.P.); (É.S.)
- Molecular Pharmacology Research Group & Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, H-7624 Pécs, Hungary
| | - Nikolett Szentes
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary; (Á.I.H.); (N.S.); (V.T.); (M.P.); (É.S.)
- Molecular Pharmacology Research Group & Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, H-7624 Pécs, Hungary
| | - Valéria Tékus
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary; (Á.I.H.); (N.S.); (V.T.); (M.P.); (É.S.)
- Molecular Pharmacology Research Group & Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, H-7624 Pécs, Hungary
| | - Maja Payrits
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary; (Á.I.H.); (N.S.); (V.T.); (M.P.); (É.S.)
- Molecular Pharmacology Research Group & Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, H-7624 Pécs, Hungary
| | - Éva Szőke
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary; (Á.I.H.); (N.S.); (V.T.); (M.P.); (É.S.)
- Molecular Pharmacology Research Group & Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, H-7624 Pécs, Hungary
- ALGONIST Biotechnologies GmBH, 1030 Vienna, Austria
| | - Emőke Oláh
- Department of Thermophysiology, Institute for Translational Medicine, Medical School, University of Pécs, H-7624 Pécs, Hungary; (E.O.); (A.G.)
| | - András Garami
- Department of Thermophysiology, Institute for Translational Medicine, Medical School, University of Pécs, H-7624 Pécs, Hungary; (E.O.); (A.G.)
| | - Eszter Fliszár-Nyúl
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.F.-N.); (M.P.)
| | - Miklós Poór
- Department of Pharmacology, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (E.F.-N.); (M.P.)
| | - Cecília Sár
- Institute of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (C.S.); (T.K.)
| | - Tamás Kálai
- Institute of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary; (C.S.); (T.K.)
| | - Szilárd Pál
- Institute of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Pécs, H-7624 Pécs, Hungary;
| | - Krisztina Percze
- Department of Molecular Biology, Institute of Biochemistry and Molecular Biology, Faculty of Medicine, Semmelweis University, H-1094 Budapest, Hungary; (K.P.); (É.N.S.); (T.M.)
| | - Éva Nagyné Scholz
- Department of Molecular Biology, Institute of Biochemistry and Molecular Biology, Faculty of Medicine, Semmelweis University, H-1094 Budapest, Hungary; (K.P.); (É.N.S.); (T.M.)
| | - Tamás Mészáros
- Department of Molecular Biology, Institute of Biochemistry and Molecular Biology, Faculty of Medicine, Semmelweis University, H-1094 Budapest, Hungary; (K.P.); (É.N.S.); (T.M.)
| | - Blanka Tóth
- Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, H-1111 Budapest, Hungary;
| | - Péter Mátyus
- Institute of Digital Health Sciences, Faculty of Health and Public Services, Semmelweis University, H-1094 Budapest, Hungary;
| | - Zsuzsanna Helyes
- Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary; (Á.I.H.); (N.S.); (V.T.); (M.P.); (É.S.)
- Molecular Pharmacology Research Group & Centre for Neuroscience, János Szentágothai Research Centre, University of Pécs, H-7624 Pécs, Hungary
- ALGONIST Biotechnologies GmBH, 1030 Vienna, Austria
- PharmInVivo Ltd., H-7629 Pécs, Hungary
- Correspondence:
| |
Collapse
|
2
|
Dallegri F, Bertolotto M, Ottonello L. A review of the emerging profile of the anti-inflammatory drug oxaprozin. Expert Opin Pharmacother 2005; 6:777-85. [PMID: 15934904 DOI: 10.1517/14656566.6.5.777] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Oxaprozin is a nonsteroidal anti-inflammatory drug characterised by a propionic acid-based structure. It is able to diffuse easily into inflamed synovial tissues after oral administration. Although discovered > 20 years ago, it is now under intensive investigation because of its unusual pharmacodynamic properties. Other than being a nonselective cyclooxygenase inhibitor, the drug is capable of inhibiting both anandamide hydrolase in neurons (median inhibitory concentration [IC50] = 85 micromol/l), with consequent potent analgesic activity, and NF-kappaB activation in inflammatory cells (IC50 = 50 micromol/l). Moreover, oxaprozin induces apoptosis of activated monocytes in a dose-dependent manner, with the effect being detectable at a concentration of 5 micromol/l and reaching the maximum activity at 50 micromol/l. As monocyte-macrophages and NF-kappaB pathways are crucial for synthesis of proinflammatory and histotoxic mediators in inflamed joints, oxaprozin appears to be endowed with pharmacodynamic properties exceeding those presently assumed as markers of classical nonsteroidal anti-inflammatory drug.
Collapse
Affiliation(s)
- Franco Dallegri
- Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova, Viale Benedetto XV, n.6, 16132 Genova, Italy.
| | | | | |
Collapse
|